Ann: Investor Presentation - Emefcy Wastewater Treatment, page-11

I just read in the Gordon Capital report about the Monaghan deal and a total investment requirement exceeding $200m and that was enough to leave me seeing red.

Anyhow, back to Emefcy, as you can see there is a wide variability in possible plant size depending on customer requirements. Companies will need more than one module, and that plus the other infrastructure needs will bring the cost up to the $140K-$550K range.

The real upside for Emefcy is the scalability of the SABRE technology – SABRE2 and SUBRE; as they make bigger modules, Emefcy’s marginal costs decrease but they can charge clients proportionally more, resulting in greater returns.

As for EBR, they are talking about z 2018 deployment, however if more money is thrown at it, I believe it can be fast tracked. Consequently, if SABRE’s commercial deployment exceeds their conservative estimates or the stock goes bananas and they do a secondary placing at a much higher price, I reckon they could easily bring EBR to fruition sooner. And EBR seems to almost be the Holy Grail of wastewater treatment.

Inferno, this offer is open to retail investors and not just existing holders. After the 100:1 consolidation, I think many of the old shareholders will be reticent about topping up, but you never know. As I mentioned in a previous post, I believe the way in is by applying for $2000 lots to help them get spread.